Nektar therapeutics (NKTR)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Revenue:
Total revenue

114,617

1,193,323

307,711

165,436

230,784

200,707

148,921

81,191

71,480

159,039

71,931

Product sales

-

-

-

-

40,155

25,152

44,846

35,399

24,864

27,412

30,116

Royalty revenue

-

-

-

-

2,967

329

1,148

4,874

10,327

7,255

5,172

Non-cash royalty revenue related to sale of future royalties

-

-

-

-

22,058

21,937

22,055

10,791

-

-

-

License, collaboration and other revenue

-

-

-

-

165,604

153,289

80,872

30,127

36,289

124,372

36,643

Operating costs and expenses:
Cost of goods sold

21,374

24,412

30,547

30,215

34,102

28,533

38,509

30,428

21,891

25,667

30,948

Research and development

434,566

399,536

268,461

203,801

182,787

147,734

190,010

148,675

126,766

108,065

95,109

General and administrative

98,712

81,443

52,364

44,275

43,266

40,925

40,532

41,614

46,760

40,986

41,006

Impairment of assets and other costs for terminated program

0

0

15,981

0

0

-

-

-

-

-

-

Impairment of long-lived assets

-

-

-

-

-

-

-

1,675

0

12,576

0

Total operating costs and expenses

554,652

505,391

367,353

278,291

260,155

217,192

269,051

222,392

195,417

187,294

167,063

Loss from operations

-440,035

687,932

-59,642

-112,855

-29,371

-16,485

-120,130

-141,201

-123,937

-28,255

-95,132

Non-operating income (expense):
Interest income

-

-

-

-

-

-

-

-

2,244

1,545

3,688

Interest expense

21,310

21,582

22,085

22,468

18,282

17,869

18,453

15,489

10,223

11,174

12,176

Non-cash interest expense on liability related to sale of future royalties

25,000

21,200

18,900

19,712

20,619

20,888

22,309

18,057

-

-

-

Loss on extinguishment of debt

-

-

-

-

-14,079

0

0

-

-

-

-

Interest income and other income (expense), net

46,335

37,571

4,520

2,387

1,680

814

1,124

3,298

-1,044

827

848

Total non-operating income (expense), net

-19

-5,207

-36,434

-39,793

-51,300

-37,943

-39,638

-30,248

-9,023

-8,802

-7,640

Loss before provision for income taxes

-440,054

682,725

-96,076

-152,648

-80,671

-54,428

-159,768

-171,449

-132,960

-37,057

-102,772

Provision for income taxes

613

1,412

616

876

506

-512

2,245

406

1,018

881

-253

Net loss

-440,667

681,313

-96,692

-153,524

-81,177

-53,916

-162,013

-171,855

-133,978

-37,938

-102,519

Basic and diluted net loss per share (in dollars per share)

-

-

-

-

-0.61

-0.42

-1.40

-1.50

-1.19

-0.40

-1.11

Weighted average shares outstanding used in computing basic and diluted net loss per share (in shares)

-

-

-

-

132,458

126,873

115,732

114,820

112,942

94,079

92,772

Net income (loss) per share
Basic ( in dollars per share)

-2.52

4.02

-0.62

-1.10

-

-

-

-

-

-

-

Diluted (in dollars per share)

-2.52

3.78

-0.62

-1.10

-

-

-

-

-

-

-

Weighted average shares outstanding used in computing net income (loss) per share
Basic (in shares)

174,993

169,600

155,953

139,596

-

-

-

-

-

-

-

Diluted (in shares)

174,993

180,119

155,953

139,596

-

-

-

-

-

-

-

Product sales
Total revenue

20,117

20,774

32,688

55,354

-

-

-

-

-

-

-

Royalty revenue
Total revenue

41,222

41,976

33,527

19,542

-

-

-

-

-

-

-

Non-cash royalty revenue related to sale of future royalties
Total revenue

36,303

33,308

30,531

30,158

-

-

-

-

-

-

-

License, collaboration and other revenue
Total revenue

16,975

1,097,265

210,965

60,382

-

-

-

-

-

-

-